[Clinical analysis of nine pediatric cases of acute myeloid leukemia with NUP98 rearrangement].
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
A retrospective case analysis was conducted on nine newly diagnosed pediatric patients with NUP98-rearranged acute myeloid leukemia (AML) who were admitted to the First Affiliated Hospital of Zhengzhou University between January 2019 to June 2025. Nine patients (3 males and 6 females) accounted for 4.2% of the 214 children diagnosed with AML during the same period. The patients' median age at diagnosis was 7 years (range: 8 months to 14 years). This type of AML was classified as M1, M4, and M5, with M5 being the most common subtype (7/9, 77.8%). The most common fusion gene type was NUP98::NSD1 (6/9, 66.7%), which was frequently accompanied by gene mutations such as FLT3-ITD and NRAS. Six cases had normal chromosome karyotypes, whereas the remaining 3 cases had abnormal karyotypes. The complete remission (CR) rate after one course of induction chemotherapy was 77.8% (7/9), and four of the children with CR underwent bridging allogeneic hematopoietic stem cell transplantation (allo-HSCT) after two to three courses of consolidation therapy, and all survived without disease. The remaining three children who continued chemotherapy had a relapse and died; whereas the two children who did not achieve CR died due to disease progression. In conclusion, at this center, pediatric AML with NUP98 rearrangement was more common in females and was often seen in the M5 subtype. NUP98::NSD1 was the most common fusion gene and was often accompanied by gene mutations, such as FLT3-ITD. Although the induction remission rate was high, the disease was prone to relaps. Allo-HSCT may improve the prognosis of these children.